Background : Gastric cancer is a widespread cancer and one of the leading causes of cancer death worldwide. In metastatic patients with HER2 overexpression the addition of Trastuzumab to first line chemotherapy improves tumor response and chance for survival. The optimal duration of Trastuzumab in this setting still unknown as well as the benefit of Trastuzumab continuation beyond progression in advanced gastric cancer.

Case presentation:We report twoMoroccan female patients who favorably responded to second line chemotherapy with Trastuzumab continuation following progressive disease to first line treatmentcontaining Trastuzumab.

Conclusion: Our report and the review of literature showed that Trastuzumab continuation beyond progressive disease in metastatic HER positive gastric cancer is safe, practical and may improve chance for survival.